Human platelet lysate is a cell culture growth additive acquired from human platelets. Restoring fetal bovine serum with HPL permits for augmentation and probable clinical grade production of stem cells by abolishing xenogeneic probabilities and relaying of bovine prions. The HPL commodities are systemized and shielded cell culture additives that sanction an escalated cell performance replicable results. The human platelet lysate market size is expanding as HPL carries plentiful platelet-procured growth elements and cytokines that invigorate cellular augmentation and sustain disparity possibility. HPL reinforces the sustenance of several cell types. Because of its excessive aggregate of growth factors and cytokines, HPL is preordained to enlarge Mesenchymal Stromal Cells and Dermal Fibroblasts. Additionally, it reinforces the development of Epidermal Keratinocytes and Endothelial Colony Forming Cells.
The global human platelet lysate market was valued at USD 50.76 million in 2022 and is expected to grow at USD 74.74 million with a CAGR of 3.9% during the forecast period 2032.
Human Platelet Lysate as an Alternative to Fetal Bovine Serum
FBS has been utilized to reinforce and develop the expansion of mammalian cells for decades. Due to several probabilities linked with FBS, many evaluations have been carried out to assess replacements to FBS with the similar efficacy and lesser risk probabilities.
HPL is a treasured addition that can be made utilizing an uncomplicated process and may effectively restore FBS in culture media for Vero and Hep-2 cell lines. While two freeze or thaw cycles are suitable, a third cycle is endorsed. HPL accommodates escalated concentrations of many growth elements such as IGF-1, VEGF, TGF-β, FGF, EGF, and PDGF than FBS. It might be restored for up to 15 months at -20 degrees Celsius to preserve its activity. The perfect application of heparin to prohibit gel formation in MEM Earl’s, MEM Hank’s, and Medium 199 media augmented with HPL is 0.25 IU/mL, while heparin addition is not needed with RPMI, PBS, normal saline, and other cell culture media carrying calcium concentrations lesser than 0.25 mM.
The market has observed a notable upswing in R&D undertakings propelled by prominent firms and governments alike. Stem cell therapy, a surfacing sphere with massive prospects for regenerative medicine, has been a central point of this escalating intrigue. The human platelet lysate market sales are soaring as the governments globally have commenced many deliberate steps to reinforce and develop R&D endeavors in stem cell therapy.
Heparin-Free HPL Ruled the Market
This segment has surfaced as a crucial element in cell culture and regenerative medicine, providing a serum-free option to conventional growth supplements. For instance, Captivate Bio instigated PLTGold human platelet lysate that is a heparin-free, xeno-free addition and is a worthier option to human AB or FBS serum for the development of MSCs and T cells. This creative commodity is gaining momentum in the global market, pushed by several elements that have transformed the environment of cell culture research and therapeutic advancement.
North America: This region is a fulcrum of stem cell research, circumscribing pluripotent stem cells, induced pluripotent stem cells, and adult stem cells. HPL is engaged to culture and augment these cells for research and development procedures and therapeutic applications.
Asia Pacific: Platelet lysate is an ace element in cell culture and regenerative medicine, pushing the demand in several research and clinical applications. The growing pervasiveness of detrimental illnesses and the growing demand for regenerative therapies is pushing the market.
HPL carries profuse growth factors and cytokines obligatory for cell growth and addition. Platelet lysate can be used as a wellspring of growth elements to replace bovine serum in a cell culture medium. In the human platelet lysate market, restoring bovine serum with HPL permits augmentation and clinical-grade production of operational mesenchymal stromal cells by detaching the probability of xenogeneic immune reactions and imparting bovine prion and viral pathogens.